.jpg)
.png)
All
The 2016 American College of Cardiology (ACC) Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-C Lowering in the Management of ASCVD Risk By Carl Orringer, MD, FNLA Following “LDL Think Tank” meeting convened by ACC in October 2015, a meeting attended by... more
Greetings from the Southwest Lipid Association (SWLA)! Our geographic region extends from the gulf shores of Louisiana to the mountains of Colorado. It also includes vast open spaces in Texas, New Mexico, and Wyoming, along with the deserts of Arizona and the plains of Oklahoma. Because it is... more
Thank you for listening to the NLA's Rewriting the Risk Equation: Lp(a) in Atherosclerotic Disease podcast. Select the appropriate certificate below then type in your name and print or save a copy for your records. Physician Certificate Nursing Certificate Pharmacist... more
The U.S. Food and Drug Administration released a Drug Safety Communication on July 20, 2021, concerning the removal of the strongest warning against using statins during pregnancy. The warning states that statins should never be used in any patients during pregnancy. After reviewing recent... more
The 2018 National Lipid Association Nominating Committee released its annual report and recommendations on Thursday.
.field-name-field-pagetitle-banner img { 100%; margin: 0 auto; }
.page-header { display: none; } NLA 3-Year Membership Bundle Ready to level up your lipid expertise and join the leaders in the field? The National Lipid Association’s 3-Year Membership Bundle is your fast-track to professional growth, advanced education, and exclusive member-... more
The National Lipid Association (NLA) announced on Thursday the recipients of its inaugural Junior Faculty Research Awards for Clinical Science and Basic Science.
Learn about Homozygous Familial Hypercholesterolemia (HoFH) on Lifetime TV’s segment Balancing Act. The next segment will air July 31. more
Controlling dyslipidemia through lowering low-density lipoprotein cholesterol (LDL-C) levels is extremely important in patients with HoFH. Unfortunately, hypercholesterolemia in FH patients is often resistant to a single drug therapy.